Elevated renal endothelin-1 clearance and mRNA levels associated with albuminuria and nephropathy in non insulin-dependent diabetes mellitus: Studies in obese fa/fa Zucker rats

Clinical Science

Volumn 93, Issue 6, 1997, Pages 565-571

  Turner, N C ^a   Morgan, P J ^a   Haynes, A C ^a   Vidgeon Hart, M ^a   Toseland, N ^a   Clapham, J C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cyclic GMP; Endothelin; Glomerulosclerosis; Hypertension; Non insulin dependent diabetes mellitus; Obese Zucker rats; Proteinuria; Thromboxane B2

Indexed keywords

CREATININE; CYCLIC GMP; ENDOTHELIN 1; MESSENGER RNA; PROSTACYCLIN; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE URINE LEVEL; ELECTROLYTE URINE LEVEL; FOCAL GLOMERULOSCLEROSIS; GENE EXPRESSION; GLOMERULOSCLEROSIS; HEMODYNAMICS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY VEIN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RAT; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; URINE VOLUME; VASOCONSTRICTION; VASODILATATION;

EID: 0030692747     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs0930565     Document Type: Article

References (33)

1. Walker JD, Viberti GC. Aetiology and pathogenesis of diabetic nephropathy: clues from early functional changes. In Pickup JC, Williams G, eds. Chronic complications of diabetes. Oxford: Blackwell Scientific Publications, 1994: 146-61.
2. Reddi AS, Camerini-Davalos RA. Diabetic nephropathy. Arch Intern Med 1990; 150: 31-43.
3. Wardle EN. Cell biology and the functional changes of diabetic nephropathy. Nephrol Dial Transplant 1992; 7: 889-95.
4. Mogensen CE, Damsgaard EM, Froland A, et al. Reduced glomerular filtration rate and cardiovascular damage in diabetes: a key role for abnormal albuminuria. Acta Diabetol 1992; 29: 201-3.
5. Hostetter TH. Diabetic nephropathy. Metabolic versus hemodynamic considerations. Diabetes Care 1992; 15: 1205-15.
6. Zatz R, Brenner BM. Pathogenesis of diabetic microangiopathy. The hemodynamic view. Am J Med 1986; 80: 443-53.
7. O'Donnell MP, Kasiske BL, Keane WF. Glomerular haemodynamic and structural alterations in experimental diabetes mellitus. FASEB J 1988; 2: 2339-47.
8. Pugiliese F, Cinotti GA, Mene P. Prostaglandins and the kidney in diabetes. Acta Diabetol 1992; 29: 218-20.
9. Craven PA, Caines MA, De Rubertis FR. Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: relationship to hyperfiltration of early diabetes. Metabolism 1987; 36: 95-103.
10. Schambelon M, Blake S, Sraer J, et al. Increased prostaglandin production from glomeruli isolated from rats with streptozotocin induced diabetes mellitus. J Clin Invest 1985; 75: 404-12.
11. Barnett AH, Leatherdale BA, Britton JR, et al. Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet 1984; i: 1322-5.
12. Simonnson MS. Endothelins: multifunctional renal peptides. Pharmacol Rev 1993; 73: 375-411.
13. Koyama H, Nishzawa Y, Mori H, et al. Plasma endothelin levels in patients with uraemia. Lancet 1989; 1: 991-2.
14. Tomita K, Ujiie K, Nakanishi T, et al. Plasma endothelin levels in patients with acute renal failure. N Engl J Med 1989; 321: 1127.
15. Bachman S, Mundel P. Nitric oxide in the kidney: synthesis, localization and function. Am J Kidney Dis 1994; 24: 112-29.
16. Kasiske BL, Cleary MP, O'Donnell MP, et al. Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 1985; 106: 598-604.
17. Kurtz TW, Morris RC, Pershadsingh HA. The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 1989; 13: 896-901.
18. Plotsky PM, Thrivikraman KV, Watts AG, et al. Hypothalamic-pituitary-adrenal axis function in the Zucker obese rat. Endocrinology (Baltimore) 1992; 130: 1931-41.
19. Schmitz PG, O'Donnell MP, Kasiske BL, et al. Renal injury in obese Zucker rats: glomerular hemodynamic alterations and effects of enalapril. Am J Physiol 1992; 32: F496-502.
20. Al-Barazanji K, Buckingham R, Turner NC, et al. BRL 49653 protects against nephropathy in obese Zucker rats: functional evidence. Diabetes 1992; 44: 71A.
21. Kasiske BL, O'Donnell MP, Keane WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia and renal injury. Hypertension 1992; 19: 1-110-15.
22. Clapham JC, Smith SA, Moore GBT, et al. Plasma leptin concentrations and OB gene expression in subcutaneous adipose tissue are not regulated acutely by physiological hyperinsulinaemia in lean and obese humans. Int J Obesity 1977; 21: 179-83.
23. Kanauchi M, Ishihara K, Nishioka H, et al. Glomerular lesions in patients with non-insulin-dependent diabetes mellitus and microalbuminuria. Intern Med 1993; 32: 753-7.
24. Nosadini R, Manzato E, Solini A, et al. Peripheral, rather than hepatic, insulin resistance and atherogenic lipoprotein phenotype predict cardiovascular complications in NIDDM. Eur J Clin Invest 1994; 24: 258-66.
25. Tetsutani T, Yamaguchi T, Kadono K, et al. Early detection of diabetic nephropathy and criteria for the initiation of therapy, Nephron 1993; 64: 69-74.
26. Jung K, Pergande M, Schimke E, et al. Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy. Clin Chem 1988; 34: 544-7.
27. Hsueh WA, Anderson PW. Hypertension, the endothelial cell, and the vascular complications of diabetes mellitus. Hypertension 1992; 20: 253-63.
28. Sarrubi D, McGiff JC, Quilley J. Renal vascular responses and eicosanoid release in diabetic rats. Am J Physiol 1989; 257: 762-8.
29. Roccatello D, Mosso R, Ferra M, et al. Urinary endothelin in glomerulonephritis patients with normal renal function. Clin Nephrol 1994; 41: 323-30.
30. Crary GS, Swan SK, O'Donnell MP, et al. The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rat. J Am Soc Nephrol 1995; 6: 1295-9.
31. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
32. Komers R, Allen TJ, Cooper ME. Role of endothelium-derived nitric oxide in the pathogenesis of the renal haemodynamic changes of experimental diabetes. Diabetes 1994; 43: 1190-7.
33. Wong KR, Xie M-H, Shi L-B, et al Urinary cGMP as biological marker of renal activity of atrial natriuretic factor. Am J Physiol 1988; 255: 1220-4.